logo-loader
Summit Therapeutics PLC

Latest data shows potential of Summit Therapeutics' DDS-04 antibiotic to treat pneumonia and sepsis

DDS-04 has now shown its potential to treat Enterobacteriaceae infections in all three key infection sites: urinary tract, bloodstream and lung

bacteria
The world desperately needs new antibiotics with resistance on the rise

Summit Therapeutics PLC (LON:SUMM) has shown that its next generation of antibiotics have the potential to treat potentially deadly infections such as pneumonia and sepsis.

AIM-quoted Summit, which is also listed on the Nasdaq in New York, tested compounds from its DDS-04 series on mice which had been infected with the two conditions.

READ: Summit in line to receive up to US$64mln in funding from US government

The DDS-04 compound cured the mice with sepsis, while it ‘significantly reduced’ the bacterial burden in the lungs in those with pneumonia.

The data build on previous preclinical research in urinary tract infections and suggest that DDS-04 has potential to treat Enterobacteriaceae infections in all three key infection sites: urinary tract, bloodstream and lung.

It is the latter two where there is the greatest unmet patient need, Summit said.

No new antibiotics this century

“There is a great need to advance truly differentiated treatments for Gram-negative bacteria, where there have been no new classes of antibiotics discovered since the last century,” said Summit’s president of R&D, David Roblin.

“In particular, the rise of untreatable and hard to treat Enterobacteriaceae infections is a frightening prospect.

“DDS-04 aligns with our strategy of targeting pathogenic bacteria and seeking to preserve patients’ good bacteria known to play an important role in overall patient health.”

In early afternoon trading, Summitt shares gqained 3.2% at 24.50p.

 -- Updates share price -- 

Quick facts: Summit Therapeutics PLC

Price: 24.5 GBX

Market: AIM
Market Cap: £39.32 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics 'taking leadership role' in development of new antibiotics

Summit Therapeutics PLC's (LON:SUMM) Dr Richard Pye speaks to Proactive London's Andrew Scott following a first quarter update on operational progress across the portfolio. Summit's currently developing three flagship treatments; Ridinilazole, designed to treat Clostridium difficile which...

on 13/6/19

2 min read